|
 |
AntifibrinolyticThis page contains recent news articles, when available, and an overview of Antifibrinolytic but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.There is evolving evidence that the use of an antifibrinolytic agent during neuromuscular scoliosis surgery can significantly decrease operative blood loss. Journal of Bone and Joint Surgery (subscription) Breastfeeding May Prevent Arthritis, Antifibrinolytic Agents ... - May 14, 2008 In a randomized clinical trial comparing three different antifibrinolytic agents, about 6% of patients who received aprotinin died within 30 days of surgery Insider Medicine, Bayer Healthcare to remove remaining Trasylol from market: FDA - May 14, 2008 The data contained in the article suggest that Trasylol appears to increase the risk for death compared with two other antifibrinolytic drugs used in the Forbes, BART Closes the Book on Aprotinin - May 20, 2008 As for mechanisms, Ray and Stein speculate that aprotinin may have been too effective as an antifibrinolytic, offsetting the procoagulatory/anticoagulatory Medscape (subscription) A Comparison of Aprotinin and Lysine Analogues in High-Risk ... - May 28, 2008 WA Background Antifibrinolytic agents are commonly used during cardiac surgery to minimize bleeding and to reduce exposure to blood products. New England Journal of Medicine (subscription), The Effect of Aprotinin on Outcome after Coronary-Artery Bypass ... - Feb 20, 2008 As compared with the use of aminocaproic acid or no antifibrinolytic agent, aprotinin use was also associated with a larger risk-adjusted increase in the New England Journal of Medicine (subscription), Aprotinin (Trasylol) Use in CABG Again Shows Extra Mortality Risk - Feb 20, 2008 Analysis by means of a risk-adjusted model revealed a mortality hazard ratio of 1.32 for patients treated with aprotinin versus no antifibrinolytic agent MedPage Today, Aprotinin under fire: Two new observational studies point to ... - Feb 20, 2008 Aprotinin-treated patients had a 32% greater risk of dying than patients who received no antifibrinolytic therapy and a 27% increased risk as compared with TheHeart.Org, Bayer Responds to Trasylol Studies - Feb 22, 2008 ...increases in serum creatinine levels than those who received aminocaproic acid (more commonly used drug to stop bleeding) or no antifibrinolytic agent. InjuryBoard.com, Aprotinin Safe in On-Pump but Not Off-Pump CABG - Feb 13, 2008 February 13, 2008 — A new retrospective analysis of patients undergoing coronary artery bypass grafting (CABG) in whom the antifibrinolytic aprotinin Medscape (subscription) Guidelines Issued for Diagnosis and Management of von Willebrand's ... - Mar 5, 2008 The antifibrinolytic drugs aminocaproic acid and tranexamic acid can also be used to treat mild mucocutaneous bleeding in VWD. Concentrates of VWF can be Medscape (subscription) Trasylol Linked to Thousands of Deaths - Feb 23, 2008 Trasylol is an antifibrinolytic agent used during cardiac surgery to reduce the risk of blood transfusions. However, two alternatives exist, InjuryBoard.com, Bayer hurt by damaging Trasylol data, sued over Kogenate - Feb 21, 2008 The study population consisted of 1343 patients (13.2%) given aprotinin, 6776 on aminocaproic acid (66.8%), and 2029 (20%) who had no antifibrinolytic Pharma Times (subscription), What's In Your Medicine Cabinet Can Kill You! - Jan 31, 2008 FDA issued a warning that this antifibrinolytic drug who’s manufacturer is “Bayer�, could cause renal failure, congestive heart failure and even death. BlackNews.com (press release), Bayer pulls Leukine from US, positive Nexavar news in Japan - Jan 24, 2008 ...a higher risk of death amongst those given Trasylol compared with two older antifibrinolytic agents, epsilon-aminocaproic acid and tranexamic acid. Pharma Times (subscription), Focus on antiplatelet therapy: An update from AHA 2007 - Dec 7, 2007 They concluded that routine use of antifibrinolytic therapy at the time of CABG might allay the previously documented concerns of major bleeding associated TheHeart.Org, EMEA advisors call for suspension for Bayer's Trasylol - Nov 23, 2007 That study was stopped after preliminary findings indicated a higher risk of death compared to two antifibrinolytic drugs used in the study, Pharma Times (subscription), Trasylol Deaths Exceed 200, FDA Says - Nov 19, 2007 ...benefits of the drug, as well as the accumulating data suggesting Trasylol increases the risk of death compared to other antifibrinolytic medications. Newsinferno.com, Drug Feared to be Defective Will be Phased Out - Nov 14, 2007 Trasylol is what is known as an antifibrinolytic drug. Antifibrinolytic drugs help slow the breakdown of blood clots and subsequent excessive bleeding. InjuryBoard.com, Loss Of Blood During Cardiac Surgeries Slashed By Antifibrinolytic ... - Oct 22, 2007 The amount of blood loss that occurs during major complex surgery is limited by the body's ability to form blood clots. This Cochrane Review concludes that MedIndia, FDA Requests Marketing Suspension of Trasylol - Nov 13, 2007 Antifibrinolytic drugs help slow the breakdown of blood clots and subsequent excessive bleeding. The preliminary data from this terminated study also Pharmaceutical Processing, FDA, Bayer Announce Suspension of Trasylol that Is Used In Heart ... - Nov 6, 2007 The other antifibrinolytic medications in the study were not creating near as much risk. The purpose of antifibrinolytic medication is to slow the breakdown Associated Content, Trial Examines Blood Conservation Using Antifibrinolytics - Nov 2, 2007 The BART (Blood Conservation using Antifibrinolytics in a Randomized Trial) study was designed to compare three antifibrinolytic drugs routinely used in eMaxHealth.com, US FDA to re-evaluate Bayer's Trasylol after panel warns of 'risk ... - Oct 25, 2007 The Data Safety Monitoring Board (DSMB) recommendation to stop patient enrolment in a study to compare Trasylol with other antifibrinolytic drugs, CNNMoney.com Aprotinin (Trasylol) Marketing Halted Over Suspected Mortality Risk - Nov 5, 2007 There, preliminary results showed an increased risk for death, though not statistically significant, with aprotinin compared with two other antifibrinolytic MedPage Today, Product Liability: Bayer Stops Sales Of Trasylol Due To Risk Of Death - Nov 5, 2007 Trasylol appeares to increase the risk for death compared to two other antifibrinolytic drugs used in the study. Antifibrinolytic drugs are used to slow the InjuryBoard.com, Canadian Trial Of Heart Surgery Drug Trasylol Halted - Oct 26, 2007 A Canadian trial involving the antifibrinolytic drug Trasylol (aprotinin), used to control bleeding in high risk heart surgery patients has been halted. Medical News Today, FDA Issues an Early Communication about an Ongoing Safety Review ... - Oct 25, 2007 The preliminary findings suggest that, compared to the antifibrinolytic drugs, epsilon-aminocaproic acid and tranexamic acid, aprotinin increases the risk PharmaLive.com (press release), Is Aprotinin (Trasylol) Safe to Use? - Oct 30, 2007 Antifibrinolytic drugs are said to reduce excessive bleeding by slowing the breakdown of blood clots that could have formed during heart surgery. Associated Content, Trasylol: Canadian Clinical Trial Halted - Oct 30, 2007 At issue was the safety and effectiveness of the three antifibrinolytic drugs. In a statement, the FDA said it would—again--evaluate the overall risks and Lawyers and Settlements, Bayer Withdraws Antibleeding Drug Trasylol - Nov 5, 2007 Trasylol is an antifibrinolytic drug, used to slow the breakdown of blood clots and subsequent excessive bleeding. The drug is widely used in heart-bypass InjuryBoard.com, FDA orders Trasylol temporarily withdrawn - Nov 5, 2007 ...had halted a Trasylol study because the drug appeared to increase the risk of death compared with two other antifibrinolytic drugs used in the study. United Press International Trial of Heart Surgery Drug Trasylol Halted; FDA issues new guidelines - Oct 27, 2007 A trial involving German drug company Bayer AG’s heart surgery antifibrinolytic drug Trasylol, used to control bleeding in high risk surgery patients, TopNews, FDA Issues Early Communication About an Ongoing Safety Review of ... - Oct 26, 2007 Antifibrinolytic drugs help slow the breakdown of blood clots and subsequent excessive bleeding. The data also suggested that fewer patients receiving the FDA.gov Trasylol Clinical Trail Halted Due to Bleeding, Death Risk - Oct 25, 2007 The Trasylol clinical trail that was ended had been comparing its effectiveness with similar drugs, known as antifibrinolytic drugs. Newsinferno.com, Trasylol (aprotinin) Trial Stopped Due to Adverse Effects - Oct 27, 2007 Med Headlines - The Food and Drug Administration (FDA) has issued a statement informing that the antifibrinolytic drug, Trasylol (aprotinin), MedHeadlines, Fresh Guidelines to Physicians on Trasylol : Bayer - Oct 26, 2007 ...data suggesting Trasylol administration increases the risk for death compared to other antifibrinolytic drugs," the US drug regulator emphasized. The Money Times, Bayer pulls its anti-clotting drug 'Trasylol' from market - Nov 6, 2007 In the trial, the use of Bayer drug aprotinin was linked to 50 percent more deaths due to hemorrhage compared with two other antifibrinolytic agents against The Money Times, Bayer stops Canadian-led drug trial over concerns of increased ... - Oct 25, 2007 ...for Trasylol and the accumulating data suggesting Trasylol administration increases the risk for death compared to other antifibrinolytic drugs. The Canadian Press, FDA Calls for the Recall of Trasylol in the Health Market - Nov 6, 2007 ...stopped a study on Trasylol because the drug appeared to increase the risk for death compared to two other antifibrinolytic drugs used in the study. Associated Content, Bayer Pulls Heart Surgery Drug Trasylol - Nov 6, 2007 Trasylol is an antifibrinolytic, a type of drug that reduces excessive bleeding by inhibiting fibrinolysis, a natural process that breaks down blood clots. Medical News Today, Bayer suspends sales of Trasylol on safety concerns - Nov 6, 2007 ...findings indicated a higher risk of death compared to two antifibrinolytic drugs used in the study, epsilon-aminocaproic acid and tranexamic acid. Pharma Times (subscription), Trasylol: AG Bayer Halts Global Sales of Troubled Drug - Nov 5, 2007 At issue was the safety, and effectiveness of the three antifibrinolytic drugs. The BART Data Safety Monitoring Board recommended two weeks ago that no new Lawyers and Settlements, Bayer Halts Trials on Trasylol Used in Bypass Surgery - Oct 27, 2007 ...is to compare the effectiveness and safety of aprotinin, aminocaproic acid and tranexamic acid — three different kinds of antifibrinolytic drugs. MedIndia, Bayer Trasylol trial halted due to high risk of death - Oct 26, 2007 The study was meant to determine if aprotinin is superior to other antifibrinolytic drugs such as epsilon-aminocaproic acid or tranexamic acid. Food Consumer, Bayer's Trasylol back in the dock as Canadian study is stopped - Oct 26, 2007 Preliminary findings suggest that Trasylol increases the risk of death compared to two antifibrinolytic drugs used in the study, epsilon-aminocaproic acid Pharma Times (subscription), Aprotinin-related mortality risk puts brakes on randomized surgery ... - Oct 25, 2007 Bayer), compared with other antifibrinolytic agents, has put the brakes on further enrollment, announced the US Food and Drug Administration, TheHeart.Org, TGF--induced EMT: mechanisms and implications for fibrotic lung ... - Aug 29, 2007 ...[CrossRef][ISI][Medline] Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with AJP-Lung Physiology (subscription) The association between saphenous vein endothelial function ... - Jul 30, 2007 The Journal of Thoracic and Cardiovascular Surgery...technique without distension and with minimal tissue handling prior to administration of heparin and/or antifibrinolytic drugs (for example, aprotonin). What's New in Pediatric Orthopaedics - May 1, 2007 Journal of Bone and Joint Surgery (subscription)Shapiro et al. analyzed the use of tranexamic acid, a synthetic antifibrinolytic agent, in patients with Duchenne muscular dystrophy undergoing posterior Nonapnea sleep disturbances seen to increase procoagulant activity - Apr 5, 2007 TheHeart.Org,The study also found that arousal frequency and apnea-hypopnea index (API) correlated with levels of the antifibrinolytic molecule FDA strengthens safety warning on aprotinin label - Dec 18, 2006 TheHeart.Org,Rockville MD - The FDA has strengthened the label safety warning for the antifibrinolytic drug aprotinin (Trasylol, Bayer), emphasizing the importance of ... Dispute highlights pitfalls in drug review process - Nov 30, 2006 Scientist,Two months have lapsed since the FDA warned that the antifibrinolytic drug aprotinin (Trasylol) could cause renal failure, congestive heart failure, stroke and ... : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |